BR112013031146A2 - liberação direcionada de compostos retinóides para as glândulas sebáceas - Google Patents
liberação direcionada de compostos retinóides para as glândulas sebáceasInfo
- Publication number
- BR112013031146A2 BR112013031146A2 BR112013031146A BR112013031146A BR112013031146A2 BR 112013031146 A2 BR112013031146 A2 BR 112013031146A2 BR 112013031146 A BR112013031146 A BR 112013031146A BR 112013031146 A BR112013031146 A BR 112013031146A BR 112013031146 A2 BR112013031146 A2 BR 112013031146A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- compositions
- sebaceous glands
- retinoid
- targeted release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
abstract disclosed herein are topical dermal compositions comprising particles, wherein the particles comprise a) a biodegradable polymer, and b) a retinoid selected from the group consisting of: and , or a pharmaceutically acceptable salt thereof, wherein the particles have an average diameter between 0.1 µm and 10 µm, and wherein the variables are as defined in the specification. the compositions are useful for treating a condition associated with excess sebum production. tradução resumo patente de invenção: "liberação direcionada de compostos retinóides para as glândulas sebáceas". são descritas composições dérmicas tópicas compreendendo partículas, em que as partículas compreendem a) um polímero biodegradável, e b) um composto retinóide selecionado do grupo consistindo em: (i) e (ii), ou sal farmaceuticamente aceitável do mesmo, em que as partículas têm um diâmetro médio entre 0,1 µm e 10 µm e em que as variáveis são como definidas no relatório descritivo. as composições são uteis no tratamento de uma condição associada com o excesso de produção de sebo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493341P | 2011-06-03 | 2011-06-03 | |
| PCT/US2012/040375 WO2012167018A1 (en) | 2011-06-03 | 2012-06-01 | Targeted delivery of retinoid compounds to the sebaceous glands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013031146A2 true BR112013031146A2 (pt) | 2017-01-31 |
Family
ID=46319186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013031146A BR112013031146A2 (pt) | 2011-06-03 | 2012-06-01 | liberação direcionada de compostos retinóides para as glândulas sebáceas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120328670A1 (pt) |
| EP (1) | EP2714016A1 (pt) |
| KR (1) | KR20140041669A (pt) |
| CN (1) | CN103732218A (pt) |
| AU (1) | AU2012262081A1 (pt) |
| BR (1) | BR112013031146A2 (pt) |
| CA (1) | CA2838179A1 (pt) |
| RU (1) | RU2013157087A (pt) |
| TW (1) | TW201311295A (pt) |
| WO (1) | WO2012167018A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120238623A1 (en) * | 2011-03-14 | 2012-09-20 | Chandraratna Roshantha A | Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists |
| US20150209343A1 (en) * | 2014-01-28 | 2015-07-30 | Allergan, Inc. | Topical dermal compositions |
| US20150209342A1 (en) * | 2014-01-28 | 2015-07-30 | Allergan, Inc. | Topical retinoid formulations, processes for making and methods of use |
| EP3177365A4 (en) * | 2014-08-06 | 2018-01-10 | Thesan Pharmaceuticals, Inc. | Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists |
| US20190133943A1 (en) * | 2015-06-18 | 2019-05-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating skin diseases |
| ES2812451T3 (es) | 2015-06-18 | 2021-03-17 | Bausch Health Ireland Ltd | Composiciones tópicas que comprenden un corticosteroide y un retinoide para tratar la psoriasis |
| US11311482B2 (en) * | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
| JP6927935B2 (ja) * | 2018-09-12 | 2021-09-01 | 株式会社マンダム | 頭皮における炎症リスクの評価方法、および抗炎症物質のスクリーニング方法 |
| CN111358766A (zh) * | 2020-04-13 | 2020-07-03 | 青岛大学 | 一种包载他扎罗汀的plga纳米粒及其制备方法、用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089509A (en) | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| US20050003007A1 (en) * | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| EP1653942A1 (en) * | 2003-07-30 | 2006-05-10 | Allergan, Inc. | Methods of therapeutic treatment using amounts of retinoid components |
| AU2005240078A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| DE102006004804A1 (de) * | 2006-01-23 | 2007-07-26 | Intendis Gmbh | Verwendung von Alkandicarbonsäuren und Retinoiden zur Behandlung entzündlicher Hauterkrankungen |
| MXPA06008988A (es) * | 2006-08-08 | 2008-02-07 | Fernando Ahumada Ayala | Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas). |
-
2012
- 2012-06-01 CA CA2838179A patent/CA2838179A1/en not_active Abandoned
- 2012-06-01 AU AU2012262081A patent/AU2012262081A1/en not_active Abandoned
- 2012-06-01 TW TW101119874A patent/TW201311295A/zh unknown
- 2012-06-01 WO PCT/US2012/040375 patent/WO2012167018A1/en active Application Filing
- 2012-06-01 RU RU2013157087/15A patent/RU2013157087A/ru unknown
- 2012-06-01 US US13/486,137 patent/US20120328670A1/en not_active Abandoned
- 2012-06-01 KR KR1020147000001A patent/KR20140041669A/ko not_active Application Discontinuation
- 2012-06-01 EP EP12728145.9A patent/EP2714016A1/en not_active Withdrawn
- 2012-06-01 CN CN201280038689.6A patent/CN103732218A/zh active Pending
- 2012-06-01 BR BR112013031146A patent/BR112013031146A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120328670A1 (en) | 2012-12-27 |
| CA2838179A1 (en) | 2012-12-06 |
| TW201311295A (zh) | 2013-03-16 |
| WO2012167018A1 (en) | 2012-12-06 |
| AU2012262081A1 (en) | 2014-01-09 |
| CN103732218A (zh) | 2014-04-16 |
| RU2013157087A (ru) | 2015-07-20 |
| EP2714016A1 (en) | 2014-04-09 |
| KR20140041669A (ko) | 2014-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013031146A2 (pt) | liberação direcionada de compostos retinóides para as glândulas sebáceas | |
| CL2017001195A1 (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 (divisional de solicitud 2844-2014) | |
| BR112014029762A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
| BR112013020767A2 (pt) | composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo | |
| AR088676A1 (es) | Composiciones para tratar superficies incluyendo sales protectoras | |
| EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112012009206A2 (pt) | agente de beta-nucleação em nanoescala para polipropileno | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| BR112015005878A2 (pt) | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas | |
| BR112013018352A2 (pt) | composição de minociclina tópica e método | |
| EA201201648A1 (ru) | Стимуляторы sgc | |
| WO2012164065A3 (en) | Process for treating straightened keratin fibres | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
| BR112015005369A2 (pt) | inibidores de usp30 e métodos para sua utilização | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
| BR112015010392A8 (pt) | Composição para tratamento de pele | |
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
| BR112015011974A8 (pt) | derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica | |
| WO2014102592A3 (en) | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof | |
| BR112014004224A2 (pt) | aparelhos e métodos para tratamento de estacas de caules de cana-de açúcar | |
| BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |